IDL Biotech AB Company Profile
Background
Overview
IDL Biotech AB is a Swedish diagnostic company specializing in the development, manufacturing, and marketing of in vitro diagnostic (IVD) products for the healthcare sector. Established in 1988, the company is headquartered in Bromma, Sweden. IDL Biotech's product portfolio is primarily divided into two main areas: Oncology and Bacteriology. In Oncology, the company offers tumor markers for various types of cancer, including breast, lung, prostate, bladder, and ovarian cancers. In Bacteriology, IDL Biotech provides diagnostic tests for bacterial infections, such as typhoid fever.
Mission and Vision
IDL Biotech's mission is to develop and deliver high-quality diagnostic solutions that enable reliable disease detection and monitoring, thereby improving patient management and outcomes. The company's vision is to be a leading provider of innovative IVD products that address critical healthcare needs globally.
Industry Significance
IDL Biotech plays a significant role in the biotechnology and medical diagnostics industry by offering specialized diagnostic tools that aid in the early detection and monitoring of various cancers and bacterial infections. The company's products contribute to personalized medicine by providing clinicians with accurate and timely information to guide treatment decisions.
Key Strategic Focus
Core Objectives
IDL Biotech aims to expand its product offerings, enhance market penetration, and strengthen its position in the global IVD market. The company focuses on developing innovative diagnostic solutions that meet the evolving needs of healthcare providers and patients.
Areas of Specialization
The company's specialization lies in the development of tumor markers for oncology and diagnostic tests for bacteriology. These products are designed to provide clinicians with reliable tools for disease detection, monitoring, and management.
Key Technologies Utilized
IDL Biotech employs advanced immunoassay technologies to develop its diagnostic products. These technologies enable the detection of specific biomarkers associated with various cancers and bacterial infections, facilitating accurate and early diagnosis.
Primary Markets Targeted
The company's primary markets include Europe and Asia, where it distributes its products through a network of international business partners. IDL Biotech's products are also available in other regions via local distributors and license agreements.
Financials and Funding
Funding History
IDL Biotech is a publicly listed company on the Swedish equities market, Spotlight Stock Market. The company has attracted investments from various shareholders, including the Labbex Group, which is the main holder. As of the latest available data, the company has approximately 2,200 shareholders.
Recent Funding Rounds
Specific details regarding recent funding rounds are not publicly disclosed. However, the company's listing on the Spotlight Stock Market indicates ongoing efforts to raise capital for business expansion and product development.
Notable Investors
The Labbex Group is a significant shareholder in IDL Biotech, reflecting confidence in the company's growth prospects and strategic direction.
Utilization of Capital
The capital raised is primarily utilized for research and development activities, product commercialization, and expanding the company's market presence. Investments are also directed towards enhancing operational capabilities and ensuring compliance with regulatory standards.
Pipeline Development
Key Pipeline Candidates
IDL Biotech's pipeline includes several diagnostic tests:
- TPS: A tumor marker for monitoring various cancers.
- TPAcyk: A tumor marker used in cancer diagnostics.
- UBC: A tumor marker for bladder cancer detection.
- MonoTotal: A tumor marker for monitoring cancer activity.
- TUBEX TF: A diagnostic test for detecting typhoid fever.
Stages of Development
These products are in various stages of commercialization, with some already available in the market and others undergoing further development to enhance their diagnostic capabilities.
Target Conditions
The diagnostic tests target conditions such as breast, lung, prostate, bladder, and ovarian cancers, as well as bacterial infections like typhoid fever.
Anticipated Milestones
The company aims to achieve regulatory approvals and expand the market reach of its products, with specific timelines dependent on regulatory processes and market dynamics.
Technological Platform and Innovation
Proprietary Technologies
IDL Biotech utilizes proprietary immunoassay technologies to develop its diagnostic products, enabling the detection of specific biomarkers associated with various diseases.
Significant Scientific Methods
The company employs advanced immunoassay techniques to ensure the accuracy and reliability of its diagnostic tests.
AI-Driven Capabilities
While specific AI-driven capabilities are not detailed in the available information, the company's focus on innovative diagnostic solutions suggests potential integration of advanced technologies to enhance product performance.
Leadership Team
Key Executives
- Charlotte Berg: Chief Executive Officer
- Lars Jakobsson: Chief Financial Officer
- Tina Yang: Chief Quality Officer
- Gustav Sten: Chief Operating Officer
- Anne-Christine Nilsson: Chief Scientific Officer
Professional Backgrounds and Contributions
The leadership team comprises professionals with extensive experience in the biotechnology and medical diagnostics sectors. Their expertise spans areas such as finance, quality assurance, operations, and scientific research, contributing to the company's strategic direction and operational success.
